Tislelizumab
Hormone Receptor Positive / HER2-negative Breast Cancer
SOLTI Breast Cancer Research Groupmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Hormone Receptor Positive / HER2-negative Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FULVESTRANT MedSIR | Phase 2 | CCC |
TAMOXIFEN Fujian Cancer Hospital | Phase 2 | CCC |
Arimidex Fujian Cancer Hospital | Phase 2 | CCC |
rc48-adc SOLTI Breast Cancer Research Group | Phase 2 | CCC |
DALPICICLIB ISETIONATE Fujian Cancer Hospital | Phase 2 | CCC |
View all 10 →
Same molecule, other indications
Tislelizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →